AZSTARYS

AZSTARYS (dexmethylphenidate hydrochloride; serdexmethylphenidate chloride) patent 9079928 expiration date extended from Jul 2032 to May 2035 in the Orange Book.

AZSTARYS patent expiration date for U.S. Patent 9,079,928 extended from Jul 2032 to May 2035.

AZSTARYS applicant changed from Commave Therapeutics SA to Commave Sub LLC, a wholly owned subsidiary of Collegium Pharmaceutical Inc.

Applicant for Azstarys (dexmethylphenidate hydrochloride; serdexmethylphenidate chloride) NDA 212994 changed from Commave Therapeutics to Commave Sub.

AZSTARYS (dexmethylphenidate hydrochloride; serdexmethylphenidate chloride) patent 9079928 expiration date extended from Jul 2032 to May 2035 in the Orange Book.

COMMAVE SUB replaced COMMAVE THERAP as the applicant of record for AZSTARYS (dexmethylphenidate hydrochloride; serdexmethylphenidate chloride) NDA 212994.

COMMAVE SUB became the applicant for AZSTARYS (dexmethylphenidate hydrochloride; serdexmethylphenidate chloride) NDA 212994, replacing COMMAVE THERAP.

Azstarys (dexmethylphenidate hydrochloride; serdexmethylphenidate chloride) NDA 212994 applicant changed from Commave Therapeutics SA to Commave Sub LLC, a wholly owned subsidiary of Collegium Pharmaceutical Inc.

AZSTARYS (dexmethylphenidate hydrochloride; serdexmethylphenidate chloride) NDA 212994 applicant changed from COMMAVE THERAPEUTICS SA to COMMAVE SUB LLC, a wholly owned subsidiary of Collegium Pharmaceutical Inc.